Psychedelic-Assisted Neuroplasticity for the Treatment of Mental Health Disorders.

The renaissance of research into psychedelics class of drugs has renewed interest for a possible psychedelic clinical therapy for treating psychiatric conditions such as treatment-resistant depression, major depressive-disorder, post-traumatic stress disorder, and other neuropsychiatric diseases. Psychedelics are known to stimulate neurogenesis and gliogenesis, reduce inflammation, and ameliorate oxidative stress, which makes them promising candidates for therapeutics in psychiatric, neurodegenerative, and movement disorders. The patent highlight showcase methods for treating mental health disorders and promoting neural plasticity.